Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1

被引:74
作者
Yamada, Koshi [1 ]
Kobayashi, Noriyoshi [1 ]
Ikeda, Tomomi [2 ]
Suzuki, Yusuke [1 ]
Tsuge, Toshinao [1 ]
Horikoshi, Satoshi [1 ]
Emancipator, Steven N. [3 ]
Tomino, Yasuhiko [1 ]
机构
[1] Juntendo Univ, Fac Med, Div Nephrol, Dept Internal Med, Tokyo, Japan
[2] Juntendo Univ, Div Mol & Biochem Res, Grad Sch Med, Tokyo, Japan
[3] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
关键词
IgA1 hinge region; T-cell cytokines; the surface IgA1-positive human B-cell line; Th2; response; BLOOD MONONUCLEAR-CELLS; MESSENGER-RNA; GALACTOSYLTRANSFERASE ACTIVITY; SELF-AGGREGATION; IMMUNE-COMPLEXES; HINGE REGION; B-CELLS; NEPHROPATHY; EXPRESSION; DIFFERENTIATION;
D O I
10.1093/ndt/gfq325
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Patients with IgA nephropathy (IgAN) have an increased amount of abnormally O-glycosylated IgA1 in circulation, in glomerular deposits and produced by tissue cells in vitro. Although increased production of Th2 cytokines by peripheral blood lymphocytes and a functional abnormality of core 1 beta 1,3-galactosyltransferase (C1 beta 3Gal-T) have been proposed as mechanisms underlying pathogenesis of IgAN, they are still obscure and are not connected. Methods. To clarify the effect of T-cell cytokines, we analysed the mRNA levels of C1 beta 3Gal-T and its molecular chaperone Cosmc, C1 beta 3Gal-T activity and subsequent O-glycosylation of IgA1 in a human B-cell line stimulated with these cytokines. The surface IgA1-positive human B-cell line was cultured with recombinant human IFN-gamma, IL-2, IL-4 or IL-5. The production and glycosylation of IgA1 were determined by sandwich ELISA and enzyme-linked lectin binding assay, respectively. The mRNA levels of C1 beta 3Gal-T and Cosmc were quantitatively measured by real-time PCR. C1 beta 3Gal-T activity was analysed using high-performance liquid chromatography. Results. IgA1 production by IL-4-stimulated cells was significantly higher than controls or after IFN-gamma or IL-5. The terminal glycosylation of secreted IgA1 was altered in response to IL-4. IL-4 stimulation significantly decreased the mRNA levels of both C1 beta 3Gal-T and Cosmc and of C1 beta 3Gal-T activity. IL-4 stimulation was clearly blocked by recombinant human IL-4 soluble receptor. Conclusions. It appears that Th2 cytokine IL-4 may play a key role in controlling glycosylation of the IgA1 hinge region.
引用
收藏
页码:3890 / 3897
页数:9
相关论文
共 46 条
[1]   Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy [J].
Allen, AC ;
Topham, PS ;
Harper, SJ ;
Feehally, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (04) :701-706
[2]   Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients [J].
Allen, AC ;
Bailey, EM ;
Brenchley, PEC ;
Buck, KS ;
Barratt, J ;
Feehally, J .
KIDNEY INTERNATIONAL, 2001, 60 (03) :969-973
[3]  
ALLEN AC, 1995, CLIN EXP IMMUNOL, V100, P470
[4]  
Amore A, 2001, J AM SOC NEPHROL, V12, P1862, DOI 10.1681/ASN.V1291862
[5]   CYTOKINE-INDUCED IMMUNOGLOBULIN PRODUCTION IN PRIMARY IGA NEPHROPATHY [J].
BAKE, AWLV ;
CROWLEYNOWICK, PA ;
KULHAVY, R ;
HERMANS, J ;
JACKSON, S ;
JULIAN, BA ;
MESTECKY, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (06) :611-617
[6]   IgA nephropathy [J].
Barratt, J ;
Feehally, J .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2088-2097
[7]  
Brockhausen I, 1998, ACTA ANAT, V161, P36
[8]   B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy [J].
Buck, K. S. ;
Smith, A. C. ;
Molyneux, K. ;
El-Barbary, H. ;
Feehally, J. ;
Barratt, J. .
KIDNEY INTERNATIONAL, 2008, 73 (10) :1128-1136
[9]  
Chintalacharuvu SR, 1997, J IMMUNOL, V159, P2327
[10]   T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation [J].
Chintalacharuvu, SR ;
Nagy, NU ;
Sigmund, N ;
Nedrud, JG ;
Amm, MEL ;
Emancipator, SN .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 126 (02) :326-333